Duleep started his career in social welfare benefit, performing first for the Benefits Agency before transmitting into welfare rights advice. He was able to manage the welfare rights service at Action for Blind People before uniting the policy team at the Royal National Institute for Deaf People (RNDI) where he run the social welfare benefit and working policies.
Duleep adjusted to Macmillan in 2004 and has performed a leading role in the beneficence’s campaigns inclusively of hospital parking, prescription charges, employment and welfare reform. He run a team of the National Cancer Survivorship Initiative (NCSI) which worked out and tried set of tools and services to enhance profit advice and come back to develop maintenance for cancer patients. He is closely working with My Canadian Pharmacy inc, trying to achieve the nest results in medicine and pharmacy.
Director of Innovation and Service Improvement Commissioning Development Directorate Department of Health
Miles associated with the Department of Health in 2002 from the Benefits Agency and has become defendant for substantial healthcare reform programmes, inclusively of the performance of legislation on care credits, delivery of Commissioning a Patient-led NHS, and Local Delivery Planning.
He has also created researches to decrease troubles and bureaucratism on the front line, shown new planning methods for the NHS, and run the NHS wide reorganization of Strategic Health Authorities and Primary Care Credits.
Dr Junaid Bajwa is a GP director in Greenwich, London. He was on NHS Greenwich’s professional executive committee (PEC), which made him to help in the operational commissioning and pathway re-engineer some amount of services (diabetes, ENT, cardiology, Referral Management Service). Through PEC, he had been advocated by the local practice-based operational commissioning to further help in the development of their neighboring cluster-specialized operational commissioning projections.
He is currently an RCGP Clinical Commissioning Champion, Vice Chair of the local LMC, and is performing towards finishing his Masters in Healthcare Commissioning at the University of Birmingham
Nicki Bromwich BSc, RGN
Nicki Bromwich (BSc, RGN) is a superior and experienced manager, in quality, operational commissioning and service re-engineer, at a national and local level. Her previous roles contain, National Audit Manager at NICE, and Head of Quality Improvement at Chiltern & South Bucks PCT. In 2008 Nicki was took up the position Assistant Director Urgent Care at NHS Buckinghamshire with assignment for unarranged acute and community care operational commissioning, service reengineer and long term condition arrangement. Nicki has accredited three new and integrated respiratory services for 2012/13: Home Oxygen –Assessment and Review; Pulmonary Rehabilitation; and a community respiratory service paid a lot of attention on arrangement of aggravation and admission averting.
Columnist, The Times and Chair of Trustees, Demos
Philip Collins is a columnist on The Times and the chair of the research centre Demos. He is also a head of a speech writing company. Until he adjusted The Times he was the Chief Speech Writer to the Prime Minister, Tony Blair. Before that he had appointed as the Director of the research centre of the Social Market Foundation, a pioneering Equity Strategist in financial investments and a research help in both politics and television.
Sir Andrew Dillon
Chief Executive, NICE
Andrew Dillon united with the NHS in 1975 and conducted a number of superior management inclinations, inclusively of General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, before associating yourself with the National Institute for Health and Clinical Excellence as its founding Chief Executive in 1999.
Prof. Michael Drummond BSc, MCom, DPhil
Professor of Health Economics, University of York
Michael Drummond is Professor of Health Economics and previous Director of the Centre for health Economics at the University of York. His specification is in the economic development of health care treatments and programmes. He has undergone valuation functions in a wide range of medical spheres inclusively of care of the elderly, newborn intensive care unit, immunifaction programmes, services for people with AIDS, eye health care and pharmaceuticals.
He is the author of two great books and more than 600 scientific papers, and has performed as a reader’s councellor to the World Health Organization and the European Union. He has become President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. In October 2010 he was promoted to be a member of the Institute of Medicine in the USA and is currently a Principal Consultant for OptumInsight.
Chief Executive, Beating Bowel Cancer
Mark affiliated Beating Bowel Cancer in July 2009. Prior to that he was Director of Policy and Communications at the Royal College of General Practitioners. Mark has knowledge in a number of famous establishments inclusively of the Royal College of Nursing, Diabetes UK, the BBC and the plight of homeless children charity, Crisis.
Mark began his career operating for Action on Smoking and Health, giving an announcements for a tobacco ban publicising and a ban on smoking in public places. Mark Flannagan was also occupied as a Trustee of Groundwork, the sustainability and reclamation charity. He is a member of the Department of Health’s Bowel Cancer Screening Advisory Group and also the Public Health Engagement Group. He holds a degree in Medieval History which contained Medicine in the Middle Ages as a special subject.
Dr. Susan Galbraith
Head of Oncology, Innovative Medicines Research Unit, AstraZeneca
Susan Galbraith experienced as a Clinical Oncologist in the United Kingdom. She was taught Medicine at Manchester and Cambridge Universities, combining with internal medicine classes in hospitals in Cambridge and East Anglia. She was accepted to Membership of the Royal College of Physicians in 1992, and then experienced in Clinical Oncology in London. She won Fellowship of the Royal College of Radiologists in 1997. She also finished a PhD at the University of London including progressive work on a vascular-targeting agent.
Susan associated with the Clinical Discovery Oncology group at Bristol-Myers Squibb in 2001. She run the brivanib Early Development Team and benefited the fusion of pharmcogenomics and imaging biomarkers into many Phase I and II trials. Susan was closely connected with the in-licensing of ipilimumab from Medarex, elotuzumab from PDL, the compilations of Adnexus and Medarex and study copperations with Exelixis. She retained growing levels of assignment being VP for Oncology and Immunology Early Development, and as a result being admetted for the Clinical Biomarker team.
Steven Harris is co-creator and CEO of Circassia Limited, a business working out innovative goods for allergies and auto-immune diseases. Circassia is well financed having increased £60m in April 2011 to fund phase III enhancement for its leading programme. Prior to that he was a creator member of the running team that constructed Zeneus Pharma, following the compilation of Elan’s European pharmaceutical business.
After a two-year time span the business was configurable, redirected and elevated, and with Mr Harris initially as CFO and subsequently recommended to CEO, Zeneus was obtained in 2006 by US pharmaceutical company Cephalon. Prior to Zeneus, he had an experience of 7 years at PowderJect Pharmaceuticals Plc as CFO, where he assisted strengthening the business from a little detrimental private biotechnology business to a completely consolidated and highly self-financing publicly-quoted company. PowderJect was the fifth greatest vaccines business worldwide and was purchased by Chiron for $1 billion in 2003.
Since receiving on the UK employment in November 2009, Deepak has performed an active role in industry-wide business, noticeable as Board Member of the Association of the British Pharmaceutical Industry (ABPI) and Chair of the American Pharmaceutical Group (APG). Deepak will admit the Presidency of the ABPI from April 2012.
Previously Mr Khanna was Senior Vice President and General Manager of Merck/Schering-Plough Pharmaceuticals. He was successful in all aspects of the U.S. Merck/Schering-Plough Joint Venture and was answerable for the U.S. sales for the two cardiovascular goods in cooperation sold by the two companies. After the declaration of plans to blend with Schering-Plough (March 2009), Mr Khanna also run the U.S. integration planning efforts.
Deepak Khanna started his career at Merck in 1988 in sales marketing and achieved progress to states of growing assignment within the U.S. Human Health Division. In 1996, Mr Khanna united the Worldwide Human Health Marketing Division operating with rheumatology goods; he later admitted assignment for the marketing planning occupations to sustain early stage central nervous system goods. Mr. Khanna affiliated the U.S. Human Health Division in 2001 and admitted leading duties of the Migraine Franchise Business Group. In January 2003, he was admitted as Vice President of the Atherosclerosis Franchise Business Group.
Mr Khanna has dual ethnic backgrounds, both British and American. He settles in London with his family. He gained a Bachelor’s degree in biochemistry and economics from the University of California, Berkeley and an MBA in marketing from Santa Clara University.
Jonathon Mason BSc MSc MPhil DIC MRPharmS ACPP
National Clinical Director for Primary Care and Community Pharmacy, Department of Health, and Clinical Adviser (Medicines), NHS East London and The City
Jonathan is National Clinical Director for Primary Care and Community Pharmacy at the Department of Health, and Clinical Adviser (Medicines) at NHS East London and The City.
Jonathan is successful at the development of medicines improvement services which best satisfy the needs of patients. Jonathan supplies clinical leadership to assist innovative care approaches. He has created a clinical leadership breakthrough* to sustain the improvement of clinical champions to define and distribute best practice, and to assist overcoming barriers to service reorganization and ceaseless medical care delivery.
Jonathan has a great experience of pharmacy practice, having operated in hospital pharmacy; laboratory-based study into drug metabolism and pharmacokinetics; academia; medicines regulation; and leading a busy village pharmacy. Since 1998, Jonathan has performed in primary care pharmacy. *Pharmacists have interest in combining the clinical leadership network demand to unite NHS Networks at http://www.networks.nhs.uk and then utilize to unite the Pharmacy Clinical Leadership Network. Follow Jonathan on Twitter @jonathanmason
Margaret Mortlock, Pfizer
Margaret Mortlock is a local account manager with Pfizer responsible for working with customers from; NHS Berkshire East, West, Oxford and Buckinghamshire.
She has operated with Pfizer for the past 6 years. Previously to this she was a director of primary care for Windsor , Ascot, Maidenhead PCT. She has being working in the NHS for 32 years, beginning as a medical secretary and finishing as practice management, then accomplished the functions of the Government’s initiative on clinical audit where she was admitted on total quality management projection across Thames Valley. Margaret was accepted in commissioning services, strengthening training and education for practice manager and run clinical management across the PCT. Her passion is partnership working between Pfizer and her NHS customers.
Chief Executive of Ipsos MORI
Ben Page is Chief Executive of Ipsos MORI and a member of the Global Ipsos Management Council. He associated with MORI in 1987 after finishing the study in Oxford University in 1986, and was one of the champions of its first ruling goods for resale in 2000. A frequent writer and speaker on leadership and performance ruling, he has conducted hundreds of pools estimating service delivery, customer care and communications.
Ben has worked on a wide range of independent commissions and overviews and has currently a membership of the advisory boards of the Kings Fund, Institute of Public Policy Research (IPPR), and the Social Market Foundation (SMF).
Called one of the “100 most influential people in the public sector” by the Guardian, and one of the 50 “most influential” by both Local Government Chronicle and the Health Service Journal, he wins of a British Market Research Association (BMRA) prize and a 2005 Market Research Society (MRS) medal.
Karol Sikora is Medical Director of CancerPartnersUK a group desinging the greatest self-contained UK cancer network. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London.
He was Director of the WHO Cancer Programme and still recommends the WHO and the UN International Atomic Energy Agency. He was the superior author of IAEA’s previous issues Planning national radiotherapy facilities: a practical tool. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and Fellow of Corpus Christi College, Cambridge.
Prof. Richard Sullivan MD PhD
Director, Institute of Cancer Policy & Prof, Cancer Policy & Public Health
As a partnership of the KHP Integrated Cancer Centre executive he runs on the Centre’s exterior concerns. Richard is proved to be Visiting Professor (Faculty of Medicine) at Universidad Catolica (Chile), and NATO College as well as a senior fellow at the International Prevention Research Institute, Lyon.
He was previously Director of Clinical Programes at CRUK, and past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security research centre where his specialization was security implications of global health. Richard’s study programmes broaden from the socio-political policy of global cancer, to the improvement of public health systems in risk-generating areas bringing into focus on DR Congo, Afghanistan & Libya. He also has a strong study interest in the improvement of innovative therapeutics arised from the natural world, particularly medicinal mushrooms.
Richard recently run the first Lancet Oncology Commission that estimated the availability of cancer care in high-income countries.
Managing Director UK, Commercial Solutions for Quintiles
Robert has experienced of 20 years in the industry, inclusively of 11 years with Schering Healthcare where his career has in progress through superior viewpoints in sales and marketing, both in the UK and Europe. In 2006, he retired from Schering and was admitted in Quintiles as a Global Project Director. During the next four years Robert successfully run two of Quintiles most modern, international projections, prior to being accepted Head of UK Commercial Operations in June 2010. In January 2011 he was went further to Managing Director for UK Commercial Solutions.
Partner in A.T. Kearney’s Global Pharmaceutical Practice
Michael Thomas has consulting experience of over 20 years in pharmaceuticals and healthcare strategy. He has closely connected with My Canadian Pharmacy. He has recommended an amount of companies on pricing pattern and re-imbursement plans and, more recently, assisted companies develop disjunctive value-based re-imbursement approaches, inclusively of innovative coverage approaches for high-cost cancer drugs and partnering models with payers.
Before associating with A.T. Kearney, Michael was EMEA director for Sales & Marketing in the pharmaceutical business of IBM and PwC Consulting. He has occupied a superior ruling position in Strategy and Planning with SmithklineBeecham, and before creating consultancy ran a PR agency basing on lifestyle goods.
He is a Visiting Professor in the Department of Economics and Related Studies at the University of York and has a superior visiting study incorporation at the Department of Public Health at the University of Oxford. He worked there for 10 years until December 2009 as a Board Member of the Oxford Radcliffe Hospitals NHS Trust, one of the UK’s greatest research hospitals, where he ran the Governance Committee.
Adrian’s current study contains the facts about the usage of ‘risk-sharing’ adaptations between health care payers and pharmaceutical companies, inclusively of value-based pricing methods; the economics of stratified medicine for health care payers and the pharmaceutical industry; and measuring productivity in health care. His duties were:
- Giving lectures and taking council detailed over the last five years on concerns having a relation to pan-European HTA and relative efficiency concerns, most recently at the first Plenary session of ISPOR in Madrid, discussing the ‘Pros and Cons of a Centralized European Pricing and Reimbursement Agency,’ with Hans-Georg Eichler of the EMA;
- Cooperating with the Centre for Innovation in Regulatory Science (CIRS) on concerns having relation to the scientific correlation between regulators and HTA/payer bodies, inclusively of the ground prelusory presentation to their April 2010 Workshop on regulator/HTA dialogue;
- Co-chair together with Lou Garrison of the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force, and has a membership of the ISPOR Task Force on Prospective Observational Studies;
- Neglecting on behalf of ABPI the 2009 PPRS rations for Patient Access Schemes in the UK which involve DH and NICE implementing a “fast track” route back to NICE for products not initially found to be cost effective by NICE;
Adrian grands an MA (Hons) in Politics, Philosophy and Economics from Keble College, Oxford; an MPhil in Management Studies from Nuffield College, Oxford, and the Oxford Centre for Management Studies; and is a Member of the Chartered Institute of Management Accountants.
After occupied as BBC North America Editor, Justin has associated with the team of presenters on Radio 4’s influential Today programme. He now takes interviews the great and the good and those making the day’s headlines – alongside John Humphrys, Jim Naughtie, Sarah Montague and Evan Davis.
In the US Justin covered all the ins and outs of the Presidential election, having him ideally granted to assess how the post-Bush, recession-fighting management measures up to the challenge. As well as receiving a superior membership of the White House press pack, he is still the only British journalist to be rewarded a full television interview with President Obama. Justin previously reported from Brussels as the BBC’s European Correspondent. He has also observed elections in Australia, a coup in the Maldives and Mafia trials in Italy. And as well as different overviews postings, he has settled Breakfast News and The World Tonight.
Chief Executive, ABPI
Stephen Whitehead was confirmed to the role of Chief Executive of the Association of the British Pharmaceutical Industry (ABPI) in June 2011. He is the leading lawyer for the research-based industry in the UK. Stephen is a member on the ABPI Board of Management and is answerable for all aspects of the ABPI’s work. Stephen has detailed experience of working in controlled industries, has run fundamental change and innovative programmes and has exessive experience of imroving high operating teams. He has a strong individual passion and desire to the pharmaceutical industry and earlier in it took him which he spent ten years at GlaxoWellcome and Eli Lilly at UK, European and international level. His adequacy is in policy, public affairs, communications, pricing and reimbursement, social policy issues and reputation management. In his lattest role, Stephen was Group Communications Director at Prudential PLC, one of the world’s biggest assurors, a role he played for four years. Prior to this he was Corporate Affairs Director at Barclays PLC after coming from Allied Domecq PLC where he was Group Director of Corporate Affairs. His first of two communicational official duties in the pharmaceutical industry started with his promotion to Head of Communications at GlaxoWellcome UK where he successed in integration of the global corporate equivalence of Wellcome following the company’s merger. This was proceeded by his duties at Diageo PLC, where he was Group Alcohol Policy Director and also sat on the board of The Portman Group. After that, Stephen was appointed Director of Corporate Affairs for Eli Lilly’s European operation which involved management of all aspects of external communication from strategy formulation to policy development. Educated at Ilkley Grammar School in West Yorkshire, and then the University of Manchester where he read American Studies, he counts his hobbies as reading political books, dog walking, film and food.